Advancing research from University of Pennsylvania, Kira was formed three years ago and made its public debut yesterday with $46m in funding.

Kira Pharmaceuticals, a US-based biotechnology developer focused on immune-mediated diseases that is exploiting research from University of Pennsylvania, emerged from stealth yesterday with a total of $46m in funding.
The cash came from 6 Dimensions Capital, an investment firm co-founded by pharmaceutical group WuXi AppTec, and Sinopharm Capital, the corporate venturing arm of pharmaceutical firm Sinopharm, as well as VC firms Quan Capital and Qiming Venture Partners.
Quan Capital was identified as the lead investor by Kira and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in